DexCom, Inc. $DXCM Shares Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,811,734 shares of the medical device company’s stock after buying an additional 191,330 shares during the quarter. Los Angeles Capital Management LLC’s holdings in DexCom were worth $123,560,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Havemeyer Place LP acquired a new position in shares of DexCom during the 4th quarter worth approximately $800,000. MCF Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $32,000. BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of DexCom by 22.9% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 67,458 shares of the medical device company’s stock worth $4,477,000 after buying an additional 12,578 shares during the period. Pinebridge Investments LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $2,778,000. Finally, PBU The Pension Fund of Early Childhood & Youth Educators acquired a new position in shares of DexCom during the 4th quarter worth approximately $3,194,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 0.4%

NASDAQ DXCM opened at $72.86 on Friday. The business has a fifty day moving average price of $64.83 and a 200 day moving average price of $66.98. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a market cap of $28.11 billion, a P/E ratio of 31.14, a P/E/G ratio of 1.14 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the prior year, the company earned $0.32 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. Research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Analyst Upgrades and Downgrades

DXCM has been the subject of several research analyst reports. Bank of America reduced their target price on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Raymond James Financial set a $81.00 target price on DexCom in a research note on Friday, May 1st. Benchmark initiated coverage on DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 target price for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. Finally, Robert W. Baird set a $80.00 price objective on DexCom in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.63.

Insider Transactions at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 42,694 shares of company stock valued at $3,029,267 in the last 90 days. 0.28% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.